
Alnylam Pharmaceuticals
Develops novel therapeutics-based RNAi and provides overviews of recent drug development programs.
Market cap
$59.5b
Enterprise value
$58.0b
Share price
$452.33 ALNY
Authorizing premium user...
Develops novel therapeutics-based RNAi and provides overviews of recent drug development programs.